Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tr1X Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners, so each pending matter is being reviewed by a different person. This relationship between the 2 pending office actions and 2 distinct examiners means that there is no personnel overlap in the current workload.
The prosecution is occurring across 2 distinct art units. QUANG NGUYEN is the busiest examiner for the company, currently holding 1 pending office action. With 2 pending office actions, 2 distinct examiners, and 2 distinct art units, the current prosecution effort is dispersed across different personnel and technical units. For practitioners, this requires a separate approach for each of the 2 pending office actions to address the specific requirements of 2 distinct art units and the preferences of 2 distinct examiners in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 1 | 37.9% | +52.6% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | NGUYEN, QUANG | — |
| 18725665 | CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | HOLTZMAN, KATHERINE ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | NGUYEN, QUANG | — |
| 18725665 | CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | NGUYEN, QUANG | 1631 | §103§112Other | Non-Final OA | — | Pending | Mar 21, 2025 |
| 18725665 | CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | HOLTZMAN, KATHERINE ANN | 1646 | §103§112Other | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTr1X Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Quang Nguyen has the most, with 1 of Tr1X Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
